| Objective This study is to evaluate the effects of VOMbp on AR-model rats and learn its immunological mechanism. To observe cytokine (Th1/Th2) and antibody(IgE, IgG, IgA) level in vivo after AR model prepared,30 min and 6 h were selected as observe points for ERP and LRP reaction separately. It could provide abundant experimental data for senior study to explain AR immunological mechanism and the anti-AR action of VOMbp. Moreover, it infers that VOMbP as a new anti-AR medicine has great clinical potential.Methods①AR rat model was established by presenting OVA mixed aluminium hydroxide to sensitize rats.②The symptom of AR rats and pathological changes of mucous membrane of nose was observed and scored, pathological section was observed under light microscope. Phlegmonosis substance histamine was determined by fluorometric method. All those assays were used to evaluate the anti-AR effects of VOMbP.③ELISA method was taken to determine cytokine and antibody level. This research involves these immunological mechanism ways:IL-4 (or IL-13) triggers isotype switches to IgE, and IgE binds to the tetrameric FcεRⅠcomplex on mast cells then causes histamine to release; IL-5 induces Eos infiltration of nasal mucosa, assists B cells to switch antibody type to IgA, IgG and their interaction; IL-12 promotes cells to secrete IFN-γand regulate IgE level together to inhabit histamine release. In addition different dosages VOMbP and other conditions were studied to observe immunological pharmacology mechanisms of VOMbP. Results①After middle dosage and high dosage of VOMbP have be used, AR symptom and pathological appearance of mucous membrane of nose was ameliorated, histamine in mucous membrane of nose and in blood decreased.②A dose-dependent two-ways regulation result has be found. VOMbP can up-regulate IL-4 in serum and IL-4, IgE in mucous membrane of nose in 30 min(ERP) after AR rats be sensitized; but down regulate IL-4, IgE and histamine in blood at 6 h(LRP) after AR rats sensitized.③IL-13 and IL-4 appeared different tendency in this study. IL-13 shows a special biological character here.④In 30 min(ERP) after AR rats sensitized, VOMbP could elevate the level of IL-5 and it could promote B cells to emerge IgA, IgG and competitively inhibited IgE and histamine which induced by IgE, released from mast cell.6 h (LRP) after AR rats sensitized, VOMbP could elevate the level of IL-5 dramatically, promote ICAM-1 level back to normal and relieve Eos infiltration in mucous membrane of nose.⑤VOMbP might rise the level of IL-12 and IFN-γto inhabit IgE and IgE caused inflammation substance histamine release. What is more, IL-12, IFN-y and histamine maintained normal in blood by high dose VOMbP.⑥In 30 min(ERP) after AR rats sensitized, the concentration of IL-4, IL-13 and IgE items have been detected twice and the result could be repeated.Conclusion VOMbp could ameliorate AR symptom and pathological appearance of mucous membrane of nose and reduce histamine both in mucous membrane of nose and blood. It indicated a promising future to develop VOMbp into a new effective drug. In addition, antibody IgE, IgG, IgA, cytokine IL-4, IL-13, IL-5, IL-12, IFN-γ, and ICAM-1 after OVA challenge 30min (ERP) and 6 h (LRP) after giving VOMbP before AR challenge, all indicators demonstrate a dose-dependent manner. In contrast, this tendency and manner might be inversed between normal group and AR group as an evidence for VOMbP effects. The result is supportive to explain AR immunological mechanism and essential to VOMbP related researches and clinical practice. |
PDF Full Text Request